Page last updated: 2024-10-29

imipramine and Supranuclear Palsy, Progressive

imipramine has been researched along with Supranuclear Palsy, Progressive in 1 studies

Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.

Supranuclear Palsy, Progressive: A degenerative disease of the central nervous system characterized by balance difficulties; OCULAR MOTILITY DISORDERS (supranuclear ophthalmoplegia); DYSARTHRIA; swallowing difficulties; and axial DYSTONIA. Onset is usually in the fifth decade and disease progression occurs over several years. Pathologic findings include neurofibrillary degeneration and neuronal loss in the dorsal MESENCEPHALON; SUBTHALAMIC NUCLEUS; RED NUCLEUS; pallidum; dentate nucleus; and vestibular nuclei. (From Adams et al., Principles of Neurology, 6th ed, pp1076-7)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nieforth, KA1
Golbe, LI1

Other Studies

1 other study available for imipramine and Supranuclear Palsy, Progressive

ArticleYear
Retrospective study of drug response in 87 patients with progressive supranuclear palsy.
    Clinical neuropharmacology, 1993, Volume: 16, Issue:4

    Topics: Amitriptyline; Carbidopa; Humans; Imipramine; Levodopa; Retrospective Studies; Supranuclear Palsy, P

1993